Should I Buy PHAR? PHAR 2026 Analysis

Should You Buy Pharming Group NV (PHAR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

20.690

1 Day change

0.49%

52 Week Range

21.340

Analysis Updated At

2026/01/26

Pharming Group NV (PHAR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show a bullish trend and analysts have raised price targets, the lack of recent news catalysts, congress trading data, and proprietary trading signals, combined with the stock's mixed short-term trend probabilities, suggest a cautious approach. It may be better to monitor the stock for further developments.

Technical Analysis

The technical indicators are bullish. The MACD histogram is positive and expanding, the RSI is neutral at 68.887, and the moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The pre-market price of $19.7 is near the first resistance level (R1: 19.742), indicating limited immediate upside potential.

Options Data

Positive Catalysts

The MACD and moving averages suggest a bullish technical setup.

Neutral/Negative Catalysts

No recent news or congress trading data available. Short-term stock trend probabilities indicate a potential -0.83% decrease in the next day and a -10.27% decrease in the next month, which could deter immediate buying.

Financial Performance

No financial data available for analysis due to an error in the snapshot. However, analysts noted strong Q3 results with $97M in sales, exceeding estimates.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are positive on the stock. Guggenheim raised the price target to $39, and Oppenheimer increased it to $42, citing strong Q3 results and promising trial data.

2 Analyst Rating

Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.5 USD with a low forecast of 37 USD and a high forecast of 42 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 20.590

Low

Averages

39.5

High

Current: 20.590

Low

Averages

39.5

High

Guggenheim

Debjit Chattopadhyay

Buy

maintain

$32 -> $39

AI Analysis

2025-12-04

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$32 -> $39

AI Analysis

2025-12-04

maintain

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Pharvaris to $39 from $32 and keeps a Buy rating on the shares after the company shared that its RAPIDe-3 trial hit on the primary and all 11 secondary endpoints. Post the RAPIDe-3 topline data readout, the firm is increasing its global peak sales estimate for deucrictibant to $1.65B from $1.4B during 2037.

Oppenheimer

Outperform

maintain

$41 -> $42

2025-11-07

Reason

Oppenheimer

Price Target

$41 -> $42

2025-11-07

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Pharming to $42 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results with $97M in sales, meaningfully above its estimates and generally in line with consensus of $90M/$98M, respectively.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHAR

Unlock Now

PHAR Should I Buy

PHAR Should I Buy

Should You Buy Pharming Group NV (PHAR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch